Human papillomavirus (HPV) vaccines reduce cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, according to a study which analysed data from England's HPV vaccine program.
Clade Therapeutics has raised US$87m in a Series A led by Syncona Ltd with participation from LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb (BMS).
Lonza has been investing in developing exosome manufacturing and characterization technologies for the past five years, and this week it ramped up its focus on that category by acquiring two sites.
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims a new report from Roots Analysis.
CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drug delivery systems for newly developed biologics along with medical and diagnostic products.
A leader from Medicines for Europe will share with CPhI Worldwide attendees a look at medicine production and offer solutions for elevating the industry.
During CPhI Worldwide, leaders from two organizations will outline how CM is taking off, potential benefits, and how to clear common obstacles to adoption.
An expert from the specialty chemicals firm (and CPhI Worldwide speaker) explains trends and developments in excipients and how they drive advancements.
The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.
BioNet and Sartorius’ BIA Separations are collaborating on production process development of mRNA vaccines: today announcing an optimized mRNA manufacturing process.
Construction of Samsung Biologics’ new facility is on track, with the CDMO saying pre-sales activities are ongoing for Plant 4, as it is known, despite the challenging business environment amid the COVID-19 pandemic.
Rentschler Biopharma and XL-protein have teamed up on the manufacture of what they say is a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I) that may open better treatment options for patients suffering from inflammation, chronic...
A clinical trial is exploring the use of the Oxford/AstraZeneca COVID-19 vaccine as an intranasal vaccine: seeing if the new route of administration could improve protection against infection and transmission.
Researchers at Stanford University and the University of North Carolina Chapel Hill are developing a microneedle vaccine patch that they believe could deliver a stronger immune response than a vaccine shot.
The Biosimilars Forum, in partnership with the Pacific Research Institute (PRI), recently released a report and interactive tool highlighting the significant costs that biosimilars can save US states.
Biolife Solutions and its subsidiary SciSafe have opened a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, located next to Schiphol Airport.
From industrializing mRNA manufacture to the implications of a potential IP waiver on COVID-19 vaccine production, hear from the experts in our free webinar this week.
Waters has announced a five-year investment to develop new analytical technology for bioprocessing and biomanufacturing with the University of Delaware.
A lot has changed over the last year since IP waiver proposals were first put forward - notably a massive rise in the production of COVID-19 vaccines. Komal Kalha of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)...
Absci Corporation says its newly opened campus in Vancouver, Washington, in the US, expands its ability to accelerate discovery and development of biologic drugs.
Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing: with its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
AION Labs, a new innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, has announced a global call for application to identify biomedical scientists and inventors to form a new startup at...
Locus Biosciences has entered a credit facility of up to US$25m with Hercules Capital, which it says will support the expansion of its precision engineered bacteriophage discovery platform engine and in-house manufacturing capacity.
Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.
Announcing a new partnership, Autolomous and Vineti say they are integrating their technology to ensure scalability when cell and gene therapies become standard of care.
Touchlight, a synthetic DNA producer, says it has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK.
The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.
AION Labs, a ‘first-of-its-kind’ innovation lab that will create and adopt AI technology to transform the process of drug discovery and development, has officially launched this month.
Avid Bioservices, Inc. is expanding its CDMO service offering into the cell and gene therapy market: constructing a purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA.
LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.
Aceto expands GMP product lines for biopharmaceutical and vaccine manufacturing with acquisition of A&C Bio Buffer, growing its manufacturing footprint and strengthening its presence in Europe.
Drug packaging and delivery system company, Gerresheimer, noted the prefillable syringes business is booming as it reported double digit organic revenue growth in Q3 2021.
CureVac is withdrawing its first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review: instead it is re-allocating its efforts to its second-generation vaccine program with GSK. ‘The goal has not changed, but the requirements to effectively...
AstraZeneca's AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.